Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in Eastern Asia has been steadily growing in recent years.
Customer preferences: Immunosuppressants are primarily used to prevent the rejection of transplanted organs. The demand for these drugs is therefore largely driven by the number of organ transplant surgeries being performed. In Eastern Asia, kidney transplants are the most common type of transplant procedure, followed by liver and heart transplants. As a result, the demand for immunosuppressants in this region is highest for drugs used in kidney transplant surgeries.
Trends in the market: One of the major trends in the Immunosuppressants market in Eastern Asia is the increasing use of generic drugs. The high cost of branded drugs has led to the development and approval of generic versions, which are more affordable for patients. This trend is expected to continue as more generic drugs become available in the market. Another trend is the growing use of combination therapy, where two or more immunosuppressants are used together to achieve better outcomes in transplant patients.
Local special circumstances: China is the largest market for immunosuppressants in Eastern Asia due to its large population and high number of transplant surgeries. However, the market in China is highly regulated, with strict pricing controls and a complex approval process for new drugs. In Japan, the market is dominated by a few major players, with limited competition from new entrants. In South Korea, the government has implemented a reimbursement system for transplant surgeries, which has led to increased demand for immunosuppressants.
Underlying macroeconomic factors: The growing prevalence of chronic diseases such as diabetes and hypertension, which can lead to organ failure, is driving the demand for transplant surgeries and immunosuppressants in Eastern Asia. The region's aging population is also contributing to the increasing demand for these drugs. Additionally, the rising middle class in countries such as China and India has led to increased healthcare spending, which is expected to further drive the growth of the Immunosuppressants market in the region.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
